Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses
2006 StandoutNobel
Cell entry mechanisms of SARS-CoV-2
2020 Standout
Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection
2018 Standout
HIV Envelope Suppresses CD4+ T Cell Activation Independent of T Regulatory Cells
2008 StandoutNobel
Controlling timing and location in vaccines
2020
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms
2014
Are US Populations Appropriate for Trials of Human Immunodeficiency Virus Vaccine?
2001
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release
2014
Practice Guidelines for the Management of Patients with Histoplasmosis
2000
Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides
2000
Asymmetric Disulfonimide‐Catalyzed Synthesis of δ‐Amino‐β‐Ketoester Derivatives by Vinylogous Mukaiyama–Mannich Reactions
2014 StandoutNobel
Canarypox Vaccines Induce Antigen‐Specific Human γδ T Cells Capable of Interferon‐γ Production
2001
Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope
2009
Strategies for containing an emerging influenza pandemic in Southeast Asia
2005 StandoutNature
Strategies for an HIV vaccine
2002
Computational Design of High-Affinity Epitope Scaffolds by Backbone Grafting of a Linear Epitope
2011 StandoutNobel
Emergence of Resistance to Fluconazole as a Cause of Failure during Treatment of Histoplasmosis in Patients with Acquired Immunodeficiency Disease Syndrome
2001
HIV VACCINES FOR PREVENTION OF INFECTION AND DISEASE IN HUMANS
2000
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data
2004
Protective immunity induced by live attenuated simian immunodeficiency virus
1998
Delivery technologies for cancer immunotherapy
2019 Standout
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
2015 Standout
Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine
2001 StandoutScience
Measuring inconsistency in meta-analyses
2003 Standout
Replicating and non-replicating viral vectors for vaccine development
2007
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
2006
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
2015
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Progress on new vaccine strategies against chronic viral infections
2004
Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66
2003
Outcome of Immunization of Cynomolgus Monkeys with Recombinant Semliki Forest Virus Encoding Human Immunodeficiency Virus Type 1 Envelope Protein and Challenge with a High Dose of SHIV-4 Virus
1997
Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies
2008
Priming of Strong, Broad, and Long-Lived HIV Type 1 p55 gag -Specific CD8 + Cytotoxic T Cells after Administration of a Virus-Like Particle Vaccine in Rhesus Macaques
2000
Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies
1999
HIV Vaccines: New Frontiers in Vaccine Development
2006
Challenges for structure-based HIV vaccine design
2009
The challenge of emerging and re-emerging infectious diseases
2004 StandoutNature
Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza
1999
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
2008
Strategies for mitigating an influenza pandemic
2006 StandoutNature
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors
2004
Amphotericin B Combined with Itraconazole or Fluconazole for Treatment of Histoplasmosis
2000
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
2008 Standout
Progress and obstacles in the development of an AIDS vaccine
2006
Preparation of Clinical‐Grade Recombinant Canarypox–Human Immunodeficiency Virus Vaccine–Loaded Human Dendritic Cells
2002 StandoutNobel
Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
2011 StandoutNobel
A Chimeric HIV-1 Envelope Glycoprotein Trimer with an Embedded Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Domain Induces Enhanced Antibody and T Cell Responses
2011
Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
2007
Recent advances in the discovery and delivery of vaccine adjuvants
2003
International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II
2012
HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity
2010 StandoutNobel
Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity
2009
Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1
2010
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
1999
SARS-CoV-2 vaccines in development
2020 StandoutNature
Amantadine and rimantadine for preventing and treating influenza A in adults
2002
Vaccines for the prevention of HIV-1 disease
2001
DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells
2003 StandoutNobel
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Human Immunodeficiency Virus Type 1envClones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
2005
Newcastle Disease Virus Expressing a Dendritic Cell-Targeted HIV Gag Protein Induces a Potent Gag-Specific Immune Response in Mice
2010 StandoutNobel
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
Antigen Clearance during Treatment of Disseminated Histoplasmosis with Itraconazole versus Fluconazole in Patients with AIDS
2002
Progress Toward an HIV Vaccine
2002
Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus
2004 StandoutNobel
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
2006
Intensified and protective CD4+ T cell immunity in mice with anti–dendritic cell HIV gag fusion antibody vaccine
2006 StandoutNobel
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
Improvements in diagnosis of histoplasmosis
2006
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
1997
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
2013 StandoutScienceNobel
Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage ofMycobacterium tuberculosisHeat Shock Protein 70 Gene to an Antigen Gene
2001 StandoutNobel
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans
2009 Standout
Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
2003 StandoutNobel
Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus
1998
Crosslinked HIV-1 envelope–CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques
2002
Invasive Candidiasis
2015 Standout
Comparison of a New Triazole, Posaconazole, with Itraconazole and Amphotericin B for Treatment of Histoplasmosis following Pulmonary Challenge in Immunocompromised Mice
2000
Inhibition of In Vivo HIV Infection in Humanized Mice by Gene Therapy of Human Hematopoietic Stem Cells with a Lentiviral Vector Encoding a Broadly Neutralizing Anti-HIV Antibody
2010
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines
1998
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity
2016
DNA vaccines: an historical perspective and view to the future
2010
Design and Synthesis of Potent Quillaja Saponin Vaccine Adjuvants
2010
Design and Characterization of Stabilized Derivatives of Human CD4D12 and CD4D1
2011 StandoutNobel
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein
2004
Controlled Ring-Opening Polymerization of Lactide and Glycolide
2004 Standout
Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+and CD4+T-Cell Responses from Chronically Infected Individuals
2001 StandoutNobel
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha Secretion
2000 StandoutNobel
Guidelines for Treatment of Candidiasis
2004 Standout
Progress on new vaccine strategies against chronic viral infections
2004
Endogenously Expressed nef Uncouples Cytokine and Chemokine Production from Membrane Phenotypic Maturation in Dendritic Cells
2002 StandoutNobel
Airborne transmission of respiratory viruses
2021 StandoutScience
Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America
2007 Standout
Advances in Oral Subunit Vaccine Design
2020
Dendritic Cells, Infected with Vesicular Stomatitis Virus-Pseudotyped HIV-1, Present Viral Antigens to CD4+ and CD8+ T Cells from HIV-1-Infected Individuals
2000 StandoutNobel
Prospects for the Future
2002 StandoutScienceNobel
RosettaRemodel: A Generalized Framework for Flexible Backbone Protein Design
2011 StandoutNobel
Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine
2001 StandoutNobel
Works of Michael C. Keefer being referenced
A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection
2000
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
1998
Safety profile of recombinant canarypox HIV vaccines
2003
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination
2009
Constrictive Pericarditis Caused by Candida glabrata in an Immunocompetent Patient: Case Report and Review of Literature
2002
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial
2008
Itraconazole Maintenance Treatment for Histoplasmosis in AIDS: A Prospective, Multicenter Trial
1997
High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects
2005
A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects
2001
Breakthrough Infections during Phase 1 and 2 Prime‐Boost HIV‐1 Vaccine Trials with Canarypox Vectors (ALVAC) and Booster Dose of Recombinant gp120 or gp160
2004
Comparison of Systemic and Mucosal Delivery of 2 Canarypox Virus Vaccines Expressing either HIV‐1 Genes or the Gene for Rabies Virus G Protein
2004
First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1
2018
Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans
1994
Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120
2006
Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity
2010
Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A
1989
Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen
1998
Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59
1996
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans
2001
Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
1998
Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1–Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A
2002
Comparative Cell‐Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV‐1 Clade BgagVaccine Prime‐Boost Regimens
2009
Preventing Discrimination Against Volunteers in Prophylactic HIV Vaccine Trials: Lessons From a Phase II Trial
1998
A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+Cytotoxic T Lymphocyte Responses in Seronegative Volunteers
1999
Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1–Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A
2002